Abstract 487P
Background
Afatinib is an irreversible second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) while gefitinib or erlotinib are reversible first-generation EGFR-TKIs.
Methods
A retrospective analysis of patients with EGFR mutant advanced lung adenocarcinoma receiving first-line afatinib versus gefitinib or erlotinib at University Malaya Medical Centre from 1st January 2015 to 31th December 2018.
Results
Of 113 patients, 24 (21.2%) received afatinib, 63 (55.8%) received gefitinib and 26 (23.0%) received erlotinib in first-line setting. Their demographic and clinical characteristics are shown in the table. Afatinib was used significantly more frequently in patients with rare or complex EGFR mutations (p = 0.005), and more often in patients with symptomatic brain metastases. The median progression-free survival (mPFS) of patients treated with afatinib (13.1 months) was longer than that of patients treated with gefitinib (10.9 months) or erlotinib (7.8 months) (p = 0.479). Patients receiving afatinib had consistently longer PFS than patients receiving gefitinib for the first 17 months and erlotinib for the first 20 months. The overall response rate was higher in patients on afatinib (75.0%) than those on gefitinib (63.5%) or erlotinib (53.8%). There was no difference in the disease control rate. Three patients (2.7%) had severe side-effects while on EGFR-TKI. Of two patients on afatinib, one had grade-3 diarrhea while another had grade 3 stomatitis, rash and paronychia. One patient had grade 3 rash on gefitinib.Table:
487P Clinical characteristic of 113 patients on first-line EGFR-TKI
Characteristics, No (%) | Afatinib (24) | Gefitinib (63) | Erlotinib (26) | p-value | |
---|---|---|---|---|---|
Symp brain mets | No Yes | 17 (70.8) 7 (29.2) | 53 (84.1) 10 (15.9) | 22 (84.6) 4 (15.4) | 0.181 |
EGFR subtype | 19 del 21 L858R Rare/complex | 16 (66.7) 2 (8.3) 6 (25.0) | 39 (61.9) 20 (31.7) 4 (6.3) | 22 (84.6) 3 (11.5) 1 (3.8) | 0.005 |
Side-effect | grade 1-2 grade 3 | 22 (91.7) 2 (8.3) | 62 (98.4) 1 (1.6) | 26 (100) 0 | 0.007 |
Objective response | Yes No | 18 (75.0) 6 (25.0) | 40 (63.5) 23 (36.5) | 14 (53.8) 12 (46.2) | 0.298 |
Disease control | Yes No | 23 (95.8) 1 (4.2) | 59 (93.7) 4 (6.3) | 24 (92.3) 2 (7.7) | 0.872 |
Median PFS | Months Event, No. (%) | 13.1 19 (79.2) | 10.9 49 (77.8) | 7.8 19 (73.1) | 0.479 |
Conclusions
Patients receiving first-line afatinib demonstrated longer mPFS than those on first-line gefitinib or erlotinib. The lack of statistical significance in this study is because of the small number of patients treated with afatinib, more frequent rare or complex EGFR mutations and more symptomatic brain metastases among afatinib treated patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract